...
search icon
howl-img

Werewolf Therapeutics Inc Share Price

HOWL
NSQ
$0.6536
-$0.01
(-1.52%)
1D
Industry: Biotechnology Sector: Health Care

Werewolf Therapeutics Inc Analyst Forecast

Werewolf Therapeutics Inc Share Price Chart

Werewolf Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$31.99M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
198.15K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.78
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.53 L
$2.38 H
$0.6536

About Werewolf Therapeutics Inc, Common Stock

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Werewolf Therapeutics Inc Stock Returns

Time FrameHOWLSectorS&P500
1-Week Return6.76%-1.08%-1.38%
1-Month Return14.39%-0.47%-1.81%
3-Month Return-29.55%2.13%1.38%
6-Month Return-51.59%17.04%5.68%
1-Year Return-56.72%6.56%11.74%
3-Year Return-79.95%16.78%65.15%
5-Year Return-95.94%34.34%73.68%

Werewolf Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-4.15M16.40M19.94M1.89M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":20.8,"profit":true},{"date":"2022-12-31","value":82.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":9.45,"profit":true}]
Cost of Revenue777.00K735.00K2.51M1.76M1.81M[{"date":"2020-12-31","value":30.96,"profit":true},{"date":"2021-12-31","value":29.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.28,"profit":true},{"date":"2024-12-31","value":72.27,"profit":true}]
Gross Profit(777.00K)(735.00K)16.40M18.18M71.00K[{"date":"2020-12-31","value":-4.27,"profit":false},{"date":"2021-12-31","value":-4.04,"profit":false},{"date":"2022-12-31","value":90.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":0.39,"profit":true}]
Gross Margin-(17.72%)100.00%91.15%3.77%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-17.72,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.15,"profit":true},{"date":"2024-12-31","value":3.77,"profit":true}]
Operating Expenses21.63M50.09M72.46M58.68M73.67M[{"date":"2020-12-31","value":29.36,"profit":true},{"date":"2021-12-31","value":67.99,"profit":true},{"date":"2022-12-31","value":98.36,"profit":true},{"date":"2023-12-31","value":79.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(22.40M)(50.09M)(56.06M)(40.50M)(73.59M)[{"date":"2020-12-31","value":-2240400000,"profit":false},{"date":"2021-12-31","value":-5008700000,"profit":false},{"date":"2022-12-31","value":-5605600000,"profit":false},{"date":"2023-12-31","value":-4050300000,"profit":false},{"date":"2024-12-31","value":-7359400000,"profit":false}]
Total Non-Operating Income/Expense7.46M208.00K4.15M7.63M5.10M[{"date":"2020-12-31","value":97.89,"profit":true},{"date":"2021-12-31","value":2.73,"profit":true},{"date":"2022-12-31","value":54.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":66.82,"profit":true}]
Pre-Tax Income(15.04M)(49.98M)(53.81M)(37.37M)(70.52M)[{"date":"2020-12-31","value":-1504000000,"profit":false},{"date":"2021-12-31","value":-4998300000,"profit":false},{"date":"2022-12-31","value":-5381000000,"profit":false},{"date":"2023-12-31","value":-3736800000,"profit":false},{"date":"2024-12-31","value":-7051500000,"profit":false}]
Income Taxes(101.00K)(216.00K)(2.25M)1.60M-[{"date":"2020-12-31","value":-6.33,"profit":false},{"date":"2021-12-31","value":-13.53,"profit":false},{"date":"2022-12-31","value":-140.72,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(14.94M)(49.77M)(51.56M)(38.96M)-[{"date":"2020-12-31","value":-1493900000,"profit":false},{"date":"2021-12-31","value":-4976700000,"profit":false},{"date":"2022-12-31","value":-5156400000,"profit":false},{"date":"2023-12-31","value":-3896410500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(15.04M)(49.98M)(53.81M)(37.30M)(70.52M)[{"date":"2020-12-31","value":-1504000000,"profit":false},{"date":"2021-12-31","value":-4998300000,"profit":false},{"date":"2022-12-31","value":-5381000000,"profit":false},{"date":"2023-12-31","value":-3729500000,"profit":false},{"date":"2024-12-31","value":-7051500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(14.94M)(49.77M)(51.56M)(37.37M)(70.52M)[{"date":"2020-12-31","value":-1493900000,"profit":false},{"date":"2021-12-31","value":-4976700000,"profit":false},{"date":"2022-12-31","value":-5156400000,"profit":false},{"date":"2023-12-31","value":-3736800000,"profit":false},{"date":"2024-12-31","value":-7051500000,"profit":false}]
EPS (Diluted)-(88.35)(1.88)(1.04)(1.66)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-8835,"profit":false},{"date":"2022-12-31","value":-188,"profit":false},{"date":"2023-12-31","value":-104,"profit":false},{"date":"2024-12-31","value":-166,"profit":false}]

Werewolf Therapeutics Inc Ratios

Werewolf Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

HOWL
Cash Ratio 3.73
Current Ratio 3.87

Werewolf Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HOWL
ROA (LTM) -40.75%
ROE (LTM) -122.43%

Werewolf Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HOWL
Debt Ratio Lower is generally better. Negative is bad. 0.63
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.37

Werewolf Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HOWL
Trailing PE NM
Forward PE NM
P/S (TTM) 52.22
P/B 1.07
Price/FCF NM
EV/R 0.67
EV/Ebitda 0.57

FAQs

What is Werewolf Therapeutics Inc share price today?

Werewolf Therapeutics Inc (HOWL) share price today is $0.6536

Can Indians buy Werewolf Therapeutics Inc shares?

Yes, Indians can buy shares of Werewolf Therapeutics Inc (HOWL) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HOWL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Werewolf Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Werewolf Therapeutics Inc (HOWL) via the Vested app. You can start investing in Werewolf Therapeutics Inc (HOWL) with a minimum investment of $1.

How to invest in Werewolf Therapeutics Inc shares from India?

You can invest in shares of Werewolf Therapeutics Inc (HOWL) via Vested in three simple steps:

  • Click on Sign Up or Invest in HOWL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Werewolf Therapeutics Inc shares
What is Werewolf Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Werewolf Therapeutics Inc (HOWL) is $2.38. The 52-week low price of Werewolf Therapeutics Inc (HOWL) is $0.53.

What is Werewolf Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Werewolf Therapeutics Inc (HOWL) is

What is Werewolf Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Werewolf Therapeutics Inc (HOWL) is 1.07

What is Werewolf Therapeutics Inc dividend yield?

The dividend yield of Werewolf Therapeutics Inc (HOWL) is 0.00%

What is the Market Cap of Werewolf Therapeutics Inc?

The market capitalization of Werewolf Therapeutics Inc (HOWL) is $31.99M

What is Werewolf Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Werewolf Therapeutics Inc is HOWL

How Can Investors Use Werewolf Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Werewolf Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Werewolf Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Werewolf Therapeutics Inc shares for Indian investors?

When investing in Werewolf Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Werewolf Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Werewolf Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Werewolf Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Werewolf Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top